Wrightson raid hints at biotech 'super-company'

Wrightson announced its $1.31-a-share stand in the market on Wednesday and finished the day with 15.05%.

It said its Genesis investment was aimed at "providing an impetus" for more collaboration in agricultural biotechnology.

The move is likely to have been approved by its 19.9% shareholder, Fonterra. Both Wrightson and Fonterra subsidiary RD1 have biotech research arms and market observers have speculated Fonterra will eventually take over Wrightson and separate the rural services and biotech divisions.

Genesis' shares have languished below the $1.70 value of its cash reserves of about $36.3 million. They traded at 97c immediately before the Wrightson stand was announced.

British trials of Genesis' Avac eczema treatment showed the drug to be safe and well-tolerated.

Comments from our readers

No comments yet

Add your comment:

Your name:
Your email:	Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Anti-spam verification:

Type the text you see in the image into the field below. You are asked to do this in order to verify that this enquiry is not being performed by an automated process.

Related News:

Mercury appoints new Chief Sustainability Officer
April 24th Morning Report
VCT - Operational performance for 9 months ended 31 March 2025
April 23rd Morning Report
TWR - Capital Return - ATO Class Ruling Obtained
THL - FY25 Trading Update
April 17th Morning Report
EBOS announces opening of Retail Offer
MCY - FY2025 EBITDAF guidance revised to $760m
April 16th Morning Report